China and Egypt Sign Cooperation Agreement for Covid-19 Vaccine

Signed a cooperation agreement for the gin and corn covid vaccine
Signed a cooperation agreement for the gin and corn covid vaccine

A cooperation protocol on Covid-19 vaccine was signed yesterday between China and Egypt. The protocol was signed by China's Ambassador to Egypt Liao Liqiang and Egyptian Deputy Health Minister Mohamed Hassani on behalf of the Chinese National Health Commission.

A cooperation protocol on Covid-19 vaccine was signed yesterday between China and Egypt. The protocol was signed by China's Ambassador to Egypt Liao Liqiang and Egyptian Deputy Health Minister Mohamed Hassani on behalf of the Chinese National Health Commission. Ambassador Liao also met with Egyptian Health Minister Hala Zayed. Liao stated that with the signing of the cooperation protocol, the cooperation between the relevant organizations of the two countries in the fields of R&D studies, production and use of the Covid-19 vaccine will be accelerated.

Pointing out that the virus does not recognize the borders of the country, Liao noted that the peoples of the country have the right to access vaccines and drugs. Liao stated that several vaccine candidates developed by China are continuing their 3rd phase trials in many countries without any problems, the emergency use program of the vaccine has been approved in China and the inactive vaccine produced by Sinopharm has also been approved by the National Medical Products Administration.

Liao added that the clinical trial data obtained so far show that vaccines manufactured by China have relatively good safety and efficacy. Hala Zayed said that Sinopharm's phase 3 clinical trials in Egypt were carried out smoothly and the safety and effectiveness of the vaccine were scientifically approved. Zayed stated that they are ready to cooperate with China in the fight against the epidemic, especially on the vaccine issue, and that they expect China to continue its support.

Source: China International Radio

Armin

sohbet

    Be the first to comment

    Comments